ライフサイエンスコーパス: coronavirus

1 on (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

2 homeostasis reduced replication of all three coronaviruses.

3 m associated with severe pneumonia caused by coronaviruses.

4 uding influenza viruses, herpes viruses, and coronaviruses.

5 y six crRNAs can target more than 90% of all coronaviruses.

6 nd non-human host genetic factors related to coronavirus, 178 involved study of non-human (animal) ho

7 uring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one m

8 ccines, therapies, and diagnostics for SARS- coronavirus 2 (CoV-2), the development of which will be

9 8 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths.

10 andemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an existing pandemic of m

11 ibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent re

12 rged virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was recently declared as

13 utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies remains undefined.

14 es against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through p

15 Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse transcriptas

16 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and rapidly

17 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019(1,2)

18 spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited an equally rapid

19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached nearly every coun

20 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in thousands of

21 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout

22 ction with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have many uses for public hea

23 ction with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is imp

24 xposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in populations, and to verify

25 tection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the environment are summar

26 valence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected on polymer

27 pare acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in young and old rh

28 th severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to contr

29 course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast.

30 ymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

31 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting

32 tected all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

33 uctions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into Scotland using a combine

34 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a global pande

35 ction with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by virus binding

36 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions o

37 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the

38 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pa

39 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing c

40 RTANCE The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of t

41 ected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown.

42 accine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the co

43 andemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccina

44 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has devastated globa

45 The SARS coronavirus 2 (SARS-CoV-2) pandemic is a global challeng

46 during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

47 data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate t

48 sex and on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case-fatal

49 tection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory samples is

50 ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing has rapidly

51 es against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a comb

52 y cells by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive inf

53 mitigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission is summarized.

54 sustained severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission networks became

55 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a global pan

56 gen, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic conditio

57 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has

58 namics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in order to inform clinical

59 ive agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a member of the Coronavir

60 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coron

61 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COV

62 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COV

63 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for co

64 carry the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while striving to find a sui

65 mission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), yet these measures are alrea

66 ction with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

67 esponse to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

68 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

69 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

70 ergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

71 mission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

72 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

73 oronavirus severe acute respiratory syndrome coronavirus 2 caused coronavirus disease 2019 cases in t

74 ction with severe acute respiratory syndrome coronavirus 2 during the coronavirus disease 2019 pandem

75 ndings for severe acute respiratory syndrome coronavirus 2 from nasopharyngeal swab and cerebral spin

76 iated with severe acute respiratory syndrome coronavirus 2 illness, but it remains unclear whether un

77 bserved in severe acute respiratory syndrome coronavirus 2 infected patients, even in the absence of

78 to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clini

79 t of 1,788 severe acute respiratory syndrome coronavirus 2 positive cases, rendering an overall admis

80 urveys for severe acute respiratory syndrome coronavirus 2 requires quantifying variations in sensiti

81 ected with severe acute respiratory syndrome coronavirus 2 requiring venovenous extracorporeal membra

82 ected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from

83 ters), for severe acute respiratory syndrome coronavirus 2 transmission, has challenged care provider

84 CE2, which severe acute respiratory syndrome coronavirus 2 uses to enter host cells, along with the h

85 action for severe acute respiratory syndrome coronavirus 2 was positive in 33.6%, whereas immunoglobu

86 caused by severe acute respiratory syndrome coronavirus 2, resulting in significant morbidity and mo

87 nation for severe acute respiratory syndrome coronavirus 2-related acute respiratory distress syndrom

88 xposure to severe acute respiratory syndrome coronavirus 2.

89 c, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of m

90 following severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection increase the risk f

91 at a greater risk of infection by the novel coronavirus 2019 (COVID-19) due to the nature of their w

92 uses, including the currently emerging novel coronavirus 2019-nCoV.

93 The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat tha

94 The 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) originally arose as p

95 n of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV

96 sinesses planned to seek funding through the Coronavirus Aid, Relief, and Economic Security (CARES) A

97 DUB mutation (Asp1772 to Ala) into a murine coronavirus and evaluated the replication and pathogenes

98 man (animal) host genetic factors related to coronavirus, and 984 involved study of non-genetic host

99 ciated with high case fatality rate of these coronaviruses as well as the host switch from animals to

100 tion in HLA genes) in the immune response to coronaviruses, as well as the clinical outcome of corona

101 y probing different scenarios based on known coronavirus biology.

102 ermine immune responses, evidence from other coronaviruses can provide clues and guide future researc

103 rmation nor evidence to suggest that the new coronavirus could be transmitted by mosquitoes".

104 infected with mouse hepatitis virus (MHV), a coronavirus (CoV), and contributes to the upregulation o

105 iridae family includes the seven known human coronaviruses (CoV) that cause mild to moderate respirat

106 d to treat the severe disease caused by this coronavirus, COVID-19.

107 Strikingly, unlike the SARS-CoV-2-like coronaviruses (CoVs) identified in bats and pangolins, S

108 cal agents responsible for zoonoses, such as coronaviruses (CoVs).

109 The outbreak of coronavirus disease (COVID-19) has caused a significant

110 own community transmission case of the novel coronavirus disease (COVID-19) in the United States, wit

111 The ongoing novel coronavirus disease (COVID-19) pandemic has already infe

112 The coronavirus disease 19 (COVID-19) pandemic has spread gl

113 more than 30% of patients with IEI had mild coronavirus disease 2019 (COVID-19) and (2) risk factors

114 from 22 patients who had recovered from mild coronavirus disease 2019 (COVID-19) and expressed anti-s

115 a pathogenic condition that has been termed coronavirus disease 2019 (COVID-19) and has reached pand

116 t efforts aimed at intercepting and treating coronavirus disease 2019 (COVID-19) and help prepare for

117 Coronavirus disease 2019 (COVID-19) caused by severe acu

118 The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acu

119 Coronavirus disease 2019 (COVID-19) causes a range of il

120 Coronavirus disease 2019 (COVID-19) continues to ravage

121 ad implementation of public health measures, coronavirus disease 2019 (COVID-19) continues to spread

122 -azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of

123 ered susceptibility and propensity to severe Coronavirus disease 2019 (COVID-19) disease in at-risk g

124 The novel coronavirus disease 2019 (COVID-19) epidemic has spread

125 Individuals with diabetes suffering from coronavirus disease 2019 (COVID-19) exhibit increased mo

126 graphy (DECTPA) in revealing vasculopathy in coronavirus disease 2019 (COVID-19) has not been fully e

127 creased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated

128 Background Neurologic complications in coronavirus disease 2019 (COVID-19) have been described,

129 Reports from centers treating patients with coronavirus disease 2019 (COVID-19) have noted that such

130 -CoV-2 is responsible for the development of coronavirus disease 2019 (COVID-19) in infected individu

131 The spread of coronavirus disease 2019 (COVID-19) in Italy prompted dr

132 tan area, we sequenced the virus that causes coronavirus disease 2019 (COVID-19) in patients seeking

133 Coronavirus disease 2019 (COVID-19) in severely affected

134 Coronavirus disease 2019 (COVID-19) is a global pandemic

135 Coronavirus disease 2019 (COVID-19) is a global public h

136 Coronavirus disease 2019 (COVID-19) is a novel threat th

137 Coronavirus disease 2019 (COVID-19) is a rapidly expandi

138 Coronavirus disease 2019 (Covid-19) is associated with d

139 Coronavirus disease 2019 (COVID-19) is caused by SARS-Co

140 d safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being t

141 The core pathology of coronavirus disease 2019 (COVID-19) is infection of airw

142 Mortality from coronavirus disease 2019 (COVID-19) is strongly associat

143 therapeutic antibodies and vaccines against coronavirus disease 2019 (COVID-19) is taking place at a

144 view, biomarkers/indicators for diagnosis of coronavirus disease 2019 (COVID-19) or detection of seve

145 The ongoing coronavirus disease 2019 (COVID-19) outbreak expanded ra

146 r underlying asthma is associated with worse coronavirus disease 2019 (COVID-19) outcomes.

147 he scientific community has responded to the coronavirus disease 2019 (COVID-19) pandemic by rapidly

148 The coronavirus disease 2019 (COVID-19) pandemic caused by S

149 l intimate partner violence (IPV) during the coronavirus disease 2019 (COVID-19) pandemic compared wi

150 The coronavirus disease 2019 (COVID-19) pandemic exposes une

151 The coronavirus disease 2019 (COVID-19) pandemic has claimed

152 The ongoing coronavirus disease 2019 (COVID-19) pandemic has heighte

153 The coronavirus disease 2019 (COVID-19) pandemic has led to

154 The ongoing coronavirus disease 2019 (COVID-19) pandemic is associat

155 The coronavirus disease 2019 (COVID-19) pandemic is exacting

156 ial distancing during the early stage of the coronavirus disease 2019 (COVID-19) pandemic poses a gre

157 formance of chest CT in the diagnosis of the coronavirus disease 2019 (COVID-19) pandemic remains und

158 Within the ivory tower of academia, the coronavirus disease 2019 (COVID-19) pandemic stands to d

159 s 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic(1).

160 us 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic(1-8).

161 ecember 2019(1,2) and is responsible for the coronavirus disease 2019 (COVID-19) pandemic(3).

162 cer have been negatively impacted during the coronavirus disease 2019 (COVID-19) pandemic, as many of

163 During the coronavirus disease 2019 (COVID-19) pandemic, Singapore

164 ological agent of the currently uncontrolled coronavirus disease 2019 (COVID-19) pandemic.

165 CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic.

166 e determining how to operate safely amid the coronavirus disease 2019 (COVID-19) pandemic.

167 failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic.

168 Deep serological profiling of 232 coronavirus disease 2019 (COVID-19) patients and 190 pre

169 cific CT protocols for imaging patients with coronavirus disease 2019 (COVID-19) pneumonia.

170 A surge of patients with coronavirus disease 2019 (COVID-19) presenting to New Yo

171 causes for the variable clinical spectrum of coronavirus disease 2019 (COVID-19) remain unknown.

172 clinician mental health in the aftermath of coronavirus disease 2019 (COVID-19) requires an evidence

173 ing effective strategies to prevent or treat coronavirus disease 2019 (COVID-19) requires understandi

174 throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing

175 ndividual variations in antibody response to coronavirus disease 2019 (COVID-19) severity, beneficial

176 s, treatment, and outcomes of critically ill coronavirus disease 2019 (COVID-19) solid organ transpla

177 tory infections before the first outbreak of coronavirus disease 2019 (COVID-19) was 99% accurate in

178 Coronavirus disease 2019 (COVID-19) was first identified

179 The novel coronavirus disease 2019 (COVID-19) was first reported i

180 hroughout the world since the first cases of coronavirus disease 2019 (COVID-19) were observed in Dec

181 roposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evid

182 Coronavirus disease 2019 (COVID-19), caused by severe ac

183 CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to mill

184 evaluates whether differences in testing for coronavirus disease 2019 (COVID-19), hospitalizations, a

185 mmonly described pulmonary expression of the coronavirus disease 2019 (COVID-19), major vascular even

186 aim of contributing to the fight against the coronavirus disease 2019 (COVID-19), numerous strategies

187 Coronavirus disease 2019 (COVID-19), the illness caused

188 ate correlates of response and protection in coronavirus disease 2019 (COVID-19), to define previous

189 virus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), uses the viral spik

190 As the Coronavirus Disease 2019 (COVID-19), which is caused by

191 h day after diagnosis, ~20% of patients with coronavirus disease 2019 (COVID-19)-associated pneumonia

192 serum samples from symptomatic PCR-confirmed coronavirus disease 2019 (COVID-19)-infected patients an

193 sed to assess simultaneously the presence of coronavirus disease 2019 (COVID-19)-specific antibodies

194 w the projected morbidity and mortality from coronavirus disease 2019 (COVID-19).

195 besity may contribute to adverse outcomes in coronavirus disease 2019 (COVID-19).

196 arities in knowledge and behavior related to coronavirus disease 2019 (COVID-19).

197 isease progression and adverse outcomes from coronavirus disease 2019 (COVID-19).

198 us 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19).

199 nd Kawasaki disease-like features related to coronavirus disease 2019 (COVID-19).

200 ognostic utility in evaluating patients with coronavirus disease 2019 (COVID-19).

201 a country that has been severely affected by coronavirus disease 2019 (COVID-19).

202 e male bias in severe disease and death from coronavirus disease 2019 (COVID-19).

203 en antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19).

204 possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19).

205 te respiratory syndrome coronavirus 2 caused coronavirus disease 2019 cases in the United States, the

206 prospective study at a quarantine center for coronavirus disease 2019 in Ho Chi Minh City, Vietnam.

207 tors for pulmonary embolism in patients with coronavirus disease 2019 include obesity, an elevated d-

208 of 27 patients were admitted to the ICU for coronavirus disease 2019 out of 1,788 severe acute respi

209 The coronavirus disease 2019 pandemic has made deployment of

210 The ongoing coronavirus disease 2019 pandemic has resulted in additi

211 espiratory syndrome coronavirus 2 during the coronavirus disease 2019 pandemic.

212 on the risks and benefits of SOT during the coronavirus disease 2019 pandemic.

213 ive approach, in the context of the emerging coronavirus disease 2019 pandemic.

214 rizing the immune and inflammatory status in coronavirus disease 2019 patients are not completely kno

215 ent reports identify that among hospitalized coronavirus disease 2019 patients, 30% require ICU care.

216 s on challenging aspects of care in managing coronavirus disease 2019 patients, current and anticipat

217 a direct impact on the clinical outcomes of coronavirus disease 2019 patients.

218 Conclusion In patients with confirmed coronavirus disease 2019 pneumonia, visual or software q

219 studies that are not exclusively focused on coronavirus disease 2019 remain relevant to patients wit

220 ischemic stroke in a pediatric patient with coronavirus disease 2019 who presented with seizure, rig

221 that such implementation of a pool test for coronavirus disease 2019 would allow expanding current s

222 f 725 consecutive hospitalized patients with coronavirus disease 2019, 108 (15%) had acute neurologic

223 outcomes for both patients with and without coronavirus disease 2019, acknowledging how many studies

224 this cohort of critically ill patients with coronavirus disease 2019, neither time from ICU admissio

225 In communities with high rates of coronavirus disease 2019, reports have emerged of childr

226 Since the onset of coronavirus disease 2019, the potential risk of dental p

227 us replication and transmission during early coronavirus disease 2019, thus advocating application of

228 isease 2019 remain relevant to patients with coronavirus disease 2019.

229 drome in children (MIS-C) is associated with coronavirus disease 2019.

230 describes a pregnant woman with symptomatic coronavirus disease who experienced a second-trimester m

231 may have numerous risk factors for acquiring Coronavirus disease-19 (COVID-19) and developing severe

232 techniques, to dissect mechanisms underlying coronavirus disease-19 (COVID-19) pathology.

233 Coronavirus disease-2019 (COVID-19) is caused by the new

234 The coronavirus disease-2019 (COVID-19) pandemic has profoun

235 During the coronavirus disease-2019 (COVID-19) pandemic, severe acu

236 eRPA does not cross-react with other common coronaviruses, does not require RNA purification, and ta

237 tious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syn

238 nactivating a dominant viral antagonist, the coronavirus endoribonuclease, dramatically alters the ho

239 This coronavirus essentiality catalog could inform ongoing dr

240 The coronavirus family member, SARS-CoV-2 has been identifie

241 I have been researching coronaviruses for more than forty years.

242 ow the highest degree of conservation across coronaviruses fostering the identification of broad-spec

243 Coronavirus genome replication is associated with virus-

244 ID-19 disease caused by the novel SARS-CoV-2 coronavirus has already brought unprecedented challenges

245 It is possible that coronavirus has an idiosyncratic action on receptors inv

246 VID-19 pandemic caused by the new SARS-CoV-2 coronavirus has imposed severe challenges on laboratorie

247 Since its emergence, the novel coronavirus has rapidly achieved pandemic proportions ca

248 assessed using the frequency of common human coronavirus (HCoV) species in key populations.

249 vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed.

250 Human coronaviruses (hCoVs) cause severe respiratory illness i

251 nd human coronavirus OC43 [n = 2], and human coronavirus HKU1 [n = 1]).

252 including severe acute respiratory syndrome coronavirus, human immunodeficiency virus 1, hepatitis C

253 f 13.9-49.6 mJ cm(-2) efficiently inactivate coronaviruses in an aerosol.

254 es to the spike protein of the 3 common cold coronaviruses in many of the donors.

255 study of non-genetic host factors related to coronavirus, including involving immunopathogenesis.

256 may also be considered for a wider range of coronaviruses, including the currently emerging novel co

257 y the envelope spike proteins of other human coronaviruses, including the currently pandemic SARS-CoV

258 Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cr

259 y have important implications for studies of coronavirus-induced disease.

260 beta-Coronavirus-induced exploitation of lysosomal organelles

261 Characterizing the mechanisms by which coronavirus infection dictates pathogenesis or counters

262 ulate host translation and restrict WT mouse coronavirus infection.

263 RIPK3)-mediated inflammatory cell deathafter coronavirus infection.

264 s is essential to promote protection against coronavirus infection; however, the underlying mechanism

265 acrophages are an important cell type during coronavirus infections because they "notice" the infecti

266 eutralising, they somehow clear infection by coronavirus, influenza and LCMV in vivo.

267 l as the closely related SARS-CoV-1 and MERS coronaviruses, is restricted to BSL-3 facilities.

268 The small ~30-kb ssRNA genome of coronaviruses makes them adept at cross-species spread w

269 aviruses, as well as the clinical outcome of coronavirus-mediated disease.

270 The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen tha

271 ARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).

272 lity, immunity, and cross-immunity for human coronavirus OC43 (HCoV-OC43) and HCoV-HKU1 using time-se

273 3], human metapneumovirus [n = 2], and human coronavirus OC43 [n = 2], and human coronavirus HKU1 [n

274 chanisms distinct from those used by endemic coronaviruses or other common cold-causing agents.

275 2019 (COVID-19) and help prepare for future coronavirus outbreaks.

276 Specificity of a pan-coronavirus (Pan-CoV) assay for a novel pathogen was ass

277 difficult question to answer, but the novel coronavirus pandemic allows us to understand how partisa

278 apidly spread in humans, causing the ongoing Coronavirus pandemic.

279 V RaTG13) and a recently identified pangolin coronavirus (Pangolin-CoV-2020).

280 SARS-CoV-2 is the novel coronavirus responsible for the current COVID-19 pandemi

281 Such non-lytic release of beta-coronaviruses results in lysosome deacidification, inact

282 re acute respiratory syndrome (SARS)-related coronavirus (SARS-CoV-2) sequences isolated in China and

283 Like other coronaviruses, SARS-CoV-2 is thought to have been transm

284 As the novel coronavirus severe acute respiratory syndrome coronaviru

285 acute respiratory infections caused by other coronaviruses (severe acute respiratory syndrome and Mid

286 eling complex, that are SARS lineage and pan-coronavirus specific, respectively.

287 d a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen

288 f histidine residues, which are conserved in coronavirus spike proteins, are predicted to be electros

289 9, has been found closely related to the bat coronavirus strain RaTG13 (Bat-CoV RaTG13) and a recentl

290 S-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains (HKU1, 229E, OC43) and three strains

291 DUBs from other viral families, particularly coronaviruses, suggests that low DUB activities of viral

292 2; previous work has been conducted on other coronaviruses that affect different species.

293 V-C flow reactors can efficiently inactivate coronaviruses through incorporation into HVAC ducts or r

294 onths, the severe acute respiratory syndrome-coronavirus type 2 (SARS-CoV-2) has spread worldwide inf

295 Here, we present the Genome Detective Coronavirus Typing Tool that can accurately identify the

296 specific reporters, we demonstrate that beta-coronaviruses utilize lysosomal trafficking for egress r

297 for development of more universal SARS-like coronavirus vaccines and therapies.

298 red for infection by SARS-CoV-2 and seasonal coronaviruses, we designed a focused high-coverage CRISP

299 ke (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study.

300 tion to a highly homologous pre-emergent bat coronavirus, WIV1-CoV, which has not yet crossed the spe